101A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy 胡永仙，浙江大学医学院附属第一医院 117Discovery of BCL-XL Heterobifunctional Degrader with Potentially Improved Therapeutic Window and Minimal Platelet Toxicity for Hematolog...
1343The Efficacy of Hetrombopag Combined with Cyclosporine a in Patients with Transfusion-Dependent Non-Severe Aplastic Anemia 何广胜,江苏省人民医院 1345Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia Wei Zhang,山东大学齐鲁医学院 1348...
How I treat prolymphocytic leukemia. Blood[J]. 2012; 120(3): 538-551. [19] Dearden C E, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route[J]. Blood, 2011, ...
14 Despite this, many practitioners remain unaware of how to diagnose or treat affected patients. VWF plays a key role in coagulation, because it serves as a carrier protein for FVIII15 and facilitates platelet binding to exposed collagen at sites of injury.16 VWD occurs when there are either...
“We don’t even know how long the remissions last. So this is really life changing for these patients,” he said during a news briefing. Talquetamab is being developed by Janssen, which paid for the study.As the investigators explained in the NEJM article, the explosion of treatment ...
What MD Anderson has done over the last 10 or 15 years has been work to improve upon the chemotherapy portion of that. That’s kind of how the CLIA backbone was designed. It added a second purine analogue—the cladribine—and increase the dose of the cytarabine to a higher-dose cytarabine...
It helps overcome anemia, fatigue and weakness. Vitamin B6 Also known as pyridoxine, B6 is involved in numerous body functions. It promotes red blood cell formation and inhibits the formation of a toxic chemical called homocys- teine, which causes cholesterol to deposit around the heart, ...
You have to treat ixazomib for 2 to 3 years to get a 4-month benefit. It is definitely a positive trial, but I think it was a little disappointing to see that small of a difference. TARGETED ONCOLOGY:What duration do you recommend for maintenance? Stewart:In the case of lenalidom...
To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or...
1086 - A Phase I/II, Intra-Patient Dose-Escalation Study of Bitopertin, a Selective Inhibitor of GlyT1 and Heme Synthesis, for Steroid-Refractory Diamond-Blackfan Anemia 1355 - Preclinical Studies of the GlyT1 Inhibitor Bitopertin in Diamond-Blackfan Anemia 3826 - Atg4a Promotes Mitochondrial Quali...